메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Catalent Announces Opening of its New Global Corporate Headquarters in Tampa, Florida

[ 메디채널 김갑성 기자 ] Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg New headquarters designed to support innovation, collaboration and growth TAMPA, Fla., Sept. 26, 2025 -- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced the opening of its new global corporate headquarters in Tampa, Fla. The state-of-the-art site has been designed to showcase innovation, collaboration and excellence, supporting the Company's commitment to drivi
- 김갑성 기자
- 2025-09-26 09:00
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth

BEIJING, SHANGHAI and BOSTON, Sept. 26, 2025 -- Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million. This action underscores their strong confidence in the Company's long-term growth prospects. In addition, the Company's share repurchase plan with an upper limit of HK$100 million, which was approved by the Board in July 2025, has already led to
- 김갑성 기자
- 2025-09-26 08:47
Building a National Lung Cancer Screening Model with AI: Early Lessons from Australia

BRISBANE, Australia and SEOUL, South Korea, Sept. 26, 2025 -- Coreline Soft announced today it will host an international webinar on Tuesday, October 14, sharing firsthand experiences and insights from the National Lung Cancer Screening Program (NLCSP) in Australia. The event, presented in collaboration with Lungscreen Australia, will explore the theme: "Building a National Model for Lung Cancer Screening in Australia." Australia officially launched its NLCSP on July 1, 2025. With three months of the program now underway, the upcoming webinar will serve
- 김갑성 기자
- 2025-09-26 07:00
어드밴시온, 2024년 기업 지속가능성 보고서 발간

4번째 연례 보고서에서는 지속 가능한 혁신, 안전, 책임감 있는 자원 관리의 꾸준한 진전 현황을 중점적으로 다룬다. 버팔로 그로브, 일리노이주, 2025년 9월 26일 -- 생명과학 분야용 완충용액과 독점 생산 특수 재료 분야의 세계 선두 기업인 어드밴시온(Advancion Corporation)(이하 '어드밴시온' 또는 '이 회사')이 오늘 2024년 기업 지속가능성 보고서를 발간한다고 발표했다. 보고서 전문은 advancionsciences.com/sustainability에서 확인할 수 있다. 어드밴시온은 포괄적인 지속가능성 보고서를 올해로 4년째 발간하고 있으며, 투명성, 책임감, 그리고 가시적인 영향력과 관련한 의지를 부단히 불태우고 있다. '과학을 원동력 삼아. 미래를 위한 설계(Driven by Science. Designed for the Future)'를 주제로 한 2024년 보고서에서는 어드밴시온이 혁신, 운영, 이해관계자 관계에 지속가능성을 접목하여 거시적으로 가치를 창출하는 방법을 주로 다루고 있다. 어드밴시온의 2024 보고서의 핵심 내용은 다음과 같다. 지속 가
- 김갑성 기자
- 2025-09-26 02:59
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

BOSTON, Sept. 25, 2025 -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Bambusa Therapeutics unveiled highly positive results from the single ascending dose portion of its ongoing Phase I healthy volunteer study of BBT001 at the European Academy of Dermatology and Venereology (EADV) 2025. The data demonstrated: A favorable safety and tolerability profile a
- 김갑성 기자
- 2025-09-25 22:04
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer

SAN FRANCISCO, Sept. 25, 2025 -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that its core pipeline product Utidelone has once again been granted as Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of pancreatic cancer. This marks the third ODD granted to Utidelone by the FDA, followi
- 김갑성 기자
- 2025-09-25 21:37
Flat Medical Establishes Clinical Advisory Board for Pain Interventions, Names Dr. Krishnan Chakravarthy as Chairman

AUSTIN, Texas, Sept. 25, 2025 -- Flat Medical, a leading innovator in medical device solutions, today announced the formation of its Clinical Advisory Board for Chronic Pain Interventions and the appointment of Dr. Krishnan Chakravarthy, MD, PhD, as its inaugural Chairman. This strategic initiative positions Flat Medical to accelerate innovation in chronic pain management technologies and expand its impact in the rapidly growing interventional pain market. Dr. Chakravarthy brings exceptional expertise as an interventional pain and spine physician, and President of the American Society
- 김갑성 기자
- 2025-09-25 21:00
iotaMotion Surpasses 1,000 Clinical Procedures Performed with iotaSOFT® --Defining a New Era in Cochlear Implant Surgery

[ 메디채널 김갑성 기자 ] Fewer than 5% of eligible patients worldwide receive cochlear implants today Hearing loss is the largest modifiable risk factor for dementia, linked to approximately 8% of global cases — more than hypertension, obesity, smoking, or depression ST. PAUL, Minn., Sept. 25, 2025 -- iotaMotion, Inc., the leader in robotic-assisted insertion systems for cochlear implantation, today announced it surpassed 1,000 clinical procedures utilizing the iotaSOFT® Insertion System. This milestone underscores growing adoption of the first and only FDA market authorized robotic-a
- 김갑성 기자
- 2025-09-25 20:33
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

[ 메디채널 김갑성 기자 ] TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations, which effectively mitigates the risk of titer drop during scale-up manufacturing to over 20,000 L. It enables a 6-month IND timeline, accelerating development of innovative therapies and their path to commercial launch. TrueSit
- 김갑성 기자
- 2025-09-25 19:42
Waterdrop Inc. Published 2024 ESG Report: Expanding Support to Vulnerable Groups, Providing Rural Medical Clinic Access to Over 500 Thousand Beneficiaries

BEIJING, Sept. 25, 2025 -- On September 25th, Waterdrop Inc. released its 2024 Environmental, Social and Governance (ESG) Report (hereinafter "the Report"), which offers an in-depth overview of the Company's progress and initiatives in corporate governance, technology innovation, product responsibility, talent development, environmental protection, and sustainable ecosystem development. The Company maintained its ESG rating at A level, underscoring its ESG progress at the forefront of the industry. The Report highlights that Waterdrop Inc. has sustained its focus on AI innova
- 황정호 기자
- 2025-09-25 13:09

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 01시 20분